What are driving factors of Atrial Fibrillation Drugs Market ? Top players - Johnson & Johnson, Pfizer, Sanofi, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and AstraZeneca

Atrial Fibrillation Drugs Market size is set to exceed USD 17.0 billion by 2025; according to a new research study published by Global Market Insights, Inc.Side effects associated with the regular intake of atrial fibrillation drugs is one of the major growth impending factors. Side effects such as excessive bleeding, tiredness, etc. will hamper market growth. Moreover, lack of awareness among people about the latest pharmaceutical therapies is another growth hindering factor.

Increasing rate of geriatric population across the world is one of the major growth augmenting factors, since people above the age of 65 years are more prone to chronic diseases such as atrial fibrillation, diabetes, hypertension, etc. Additionally, rising prevalence of cardiovascular diseases, especially in the U.S. will further boost the growth of atrial fibrillation drugs market in the forthcoming years.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/3253

Anticoagulants segment of atrial fibrillation drugs market was valued at around USD 11,554.6 million in the year 2018. Anticoagulants were introduced with an aim to reduce the rate of stroke in individuals suffering from atrial fibrillation. Patients with atrial fibrillation should be considered for antiplatelet or anticoagulation therapy based on patient's age and presence of other risk factors. A significant rise in the incidence of atrial fibrillation associated strokes over the recent years have increased the demand of anticoagulants thus, augmenting atrial fibrillation market growth.

Use of atrial fibrillation drugs for paroxysmal condition will grow at 2.9% over the estimation period. The paroxysmal atrial fibrillation occurs when there are irregular electric pathways in the heart and the heart is not pumping enough oxygen-rich blood, that leads to erratic heart rates that can last for upto 24 hours. The occurrence of paroxysmal atrial fibrillation is evidently increasing among the geriatric population as well as in young generation owing to rise in factors such as valvular disfunctions, coronary artery disease, previous heart surgery etc. Hence, the above mentioned reasons will augment the growth of atrial fibrillation drugs market.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/3253

Application of atrial fibrillation drugs market in heart rhythm control was valued at USD 3,312.4 million in the year 2018. Heart rhythm control is the maintenance and acute restoration of sinus rhythm in patients suffering from atrial fibrillation. The achievement of heart rhythm control can indeed reduce atrial fibrillation-associated mortality and morbidity. Patients that have coexistent cardiovascular diseases such as obstructive sleep apnea, hypertension, valvular heart disease and heart failure have a much higher increased risk for progression of arrhythmia. Hence, the increasing incidence of such cardiovascular diseases coupled with geriatric population will augment heart rhythm control segment growth.

Oral atrial fibrillation drug administration market will grow at 3.1% over the forecast period. The aim of medical therapy for patients suffering from atrial fibrillation are to avoid the risk of complications, sustain sinus rhythm and minimize atrial fibrillation symptoms. Oral drug therapies such as warfarin denotes the cornerstone of anticoagulant oral therapy for patients at high risk of thromboembolic events. With increase in incidence of atrial strokes across the world, oral drug therapies are experiencing an upward trajectory of atrial fibrillation dugs market growth.

The use of atrial fibrillation drugs in hospitals is estimated to grow at 3% over the forecast period. Rising popularity of anticoagulant and antiarrhythmic drugs in developed and developing countries will strongly contribute to larger demand for atrial fibrillation drugs in hospitals. Moreover, increasing investments and partnerships with various manufacturing firms will further augment the atrial fibrillation drugs market growth.

The U.S. atrial fibrillation drugs market is the largest in the world and projected to expand at a CAGR of 2.4% over the forecast period. During the forecast timeframe, it will continue to grow with stable growth and lead the industry at a global level. Increasing geriatric population, rising venture capital investments by manufacturing firms, growing adoption rate of new pharmaceutical drugs to address severe conditions of patients suffering from atrial fibrillation in the country should drive the U.S. atrial fibrillation drugs market during the projection years.

Some of the key industry players operating in the global atrial fibrillation market are Johnson & Johnson, Pfizer, Sanofi S.A, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Co., Daiichi Sankyo Company, Limited and AstraZeneca. The industry participants emphasize on acquisitions and mergers, geographical expansion and novel product developments to strengthen their position in the market and gain competitive advantage over its peers.

Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definition
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Atrial fibrillation drugs industry 3600 synopsis, 2014 - 2025 (USD Million)
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Atrial fibrillation type trends
2.1.4. Application trends
2.1.5. Route of Administration trends
2.1.6. End-use trends
2.1.7. Regional trends
Chapter 3. Atrial Fibrillation Drugs Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2014 - 2025 (USD Million)
3.3. Industry impact factors
3.3.1. Growth drivers
3.3.1.1. Increase in prevalence of cardiovascular diseases in developed regions of North America and Europe
3.3.1.2. Rise in demand and need for unmet atrial fibrillation drug therapy
3.3.1.3. Growing geriatric population in Asia Pacific and Latin America
3.3.1.4. Launch of Direct Oral Anticoagulants (DOACs)
3.3.2. Industry pitfalls & challenges
3.3.2.1. High cost of the anticoagulant drugs
3.3.2.2. Adverse drug side effects
3.3.2.3. Lack of awareness regarding medical therapy in underdeveloped and developing regions
3.4. Growth potential analysis
3.4.1. By product
3.4.2. By atrial fibrillation type
3.4.3. By application
3.4.4. By route of administration
3.4.5. By end-use
3.5. Global atrial fibrillation prevalence, 2017
3.6. Drug approval scenario
3.6.1. U.S. FDA (U.S. Food and Drug Administration)
3.6.2. Europe EMA (European Medicines Agency)
3.6.3. China CFDA (China Drug Administration)
3.6.4. Australia TGA (Australian Therapeutic Goods Administration)
3.7. Proportion of atrial fibrillation patients on atrial fibrillation drug therapy, 2018
3.7.1. North America
3.7.2. Europe
3.7.3. Asia Pacific
3.7.4. Latin America
3.7.5. Middle East and Africa
3.8. Proportion of atrial fibrillation patients on direct oral anticoagulants (DOACs) drug therapy
3.8.1. North America
3.8.2. Europe
3.8.3. Asia Pacific
3.8.4. Latin America
3.8.5. Middle East and Africa
3.9. Atrial fibrillation drugs pricing analysis
3.9.1. Antiarrhythmic drugs
3.9.2. Anticoagulant drugs
3.10. Major atrial fibrillation anticoagulant drugs market share analysis, 2017
3.11. Global atrial fibrillation drugs prescription pattern, 2014 – 2025
3.11.1. Antiarrhythmic drugs
3.11.2. Anticoagulant drugs
3.11.2.1. Vitamin K antagonists (Warfarin)
3.11.2.2. Novel oral anticoagulants (NOACs)
3.11.2.2.1. Direct thrombin inhibitors (Dabigatran - Pradaxa)
3.11.2.2.2. Direct factor Xa inhibitors
3.11.2.2.2.1. Apixaban (Eliquis)
3.11.2.2.2.2. Betrixaban (Bevyxxa)
3.11.2.2.2.3. Edoxaban (Savaysa/Lixiana)
3.11.2.2.2.4. Rivaroxaban (Xarelto)
3.12. Technology landscape
3.12.1. New atrial fibrillation drugs
3.12.1.1. Antiarrhythmic drugs
3.12.1.2. Anticoagulant drugs
3.12.2. Future of drug therapy in atrial fibrillation
3.12.2.1. Antiarrhythmic drugs
3.12.2.2. Anticoagulant drugs
3.13. Porter’s analysis
3.14. Competitive landscape, 2017
3.14.1. Strategy dashboard
3.15. PESTEL analysis

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Blog : http://news-researchers.com/

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

This release was published on openPR.